106P Impact of molecular alterations in advanced biliary tract cancer (BTC) patients (pts) treated with cisplatin, gemcitabine, durvalumab (CGD): A large global studyF. Lo Prinzi, A. Casadei Gardini, M. Rimini et al.|ESMO Open|2025Cited by 0
Cisplatin-gemcitabine-durvalumab reintroduction in advanced biliary tract cancer: a multinational real-world analysisSilvia Camera, G. Aprile, Oluseyi Abidoye et al.|ESMO Open|2026Cited by 0